Market Research Logo

Sareum Holdings Plc (SAR) - Financial and Strategic SWOT Analysis Review

Sareum Holdings Plc (SAR) - Financial and Strategic SWOT Analysis Review

-provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhibitor Library). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (Checkpoint Kinase 1), Aurora+FLT3 kinase, VEGFR-3 (FLT4) kinase, Fatty Acid Synthase (FASN), Tyrosine kinase 2 (TYK2), ALK Kinase, FLT3 and Microtubule binding agents. Sareum’s Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Pampisford Cambridge, the UK.

Sareum Holdings Plc Key Recent Developments

Oct 19,2017: Sareum Holdings: Final Results for the year ended 30 June 2017
Feb 20,2017: Sareum Holdings Announces Half-Yearly Results For The Six Months Ended 31 December 2016
Nov 02,2016: Sareum Holdings: Final Results
Aug 03,2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Sareum Holdings Plc - Key Facts
Sareum Holdings Plc - Key Employees
Sareum Holdings Plc - Key Employee Biographies
Sareum Holdings Plc - Major Products and Services
Sareum Holdings Plc - History
Sareum Holdings Plc - Company Statement
Sareum Holdings Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Sareum Holdings Plc - Business Description
Sareum Holdings Plc - Corporate Strategy
Sareum Holdings Plc - SWOT Analysis
SWOT Analysis - Overview
Sareum Holdings Plc - Strengths
Sareum Holdings Plc - Weaknesses
Sareum Holdings Plc - Opportunities
Sareum Holdings Plc - Threats
Sareum Holdings Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Sareum Holdings Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 19, 2017: Sareum Holdings: Final Results for the year ended 30 June 2017
Feb 20, 2017: Sareum Holdings Announces Half-Yearly Results For The Six Months Ended 31 December 2016
Nov 02, 2016: Sareum Holdings: Final Results
Aug 03, 2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Sareum Holdings Plc, Key Facts
Sareum Holdings Plc, Key Employees
Sareum Holdings Plc, Key Employee Biographies
Sareum Holdings Plc, Major Products and Services
Sareum Holdings Plc, History
Sareum Holdings Plc, Subsidiaries
Sareum Holdings Plc, Key Competitors
Sareum Holdings Plc, Ratios based on current share price
Sareum Holdings Plc, Annual Ratios
Sareum Holdings Plc, Interim Ratios
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Sareum Holdings Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Sareum Holdings Plc, Performance Chart (2013 - 2017)
Sareum Holdings Plc, Ratio Charts
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report